as compared with the pre-BCID group [40.2 hours (pre) vs 24.6 hours (post) vs 25.9 hours (ASP); P = 0.46].
Direct Disk Diffusion Susceptibility Testing for
Background. In order to detect multidrug resistant strains of bacteria, our laboratory routinely performs direct susceptibility (DS), in addition to standardized susceptibilities (SS), testing from positive blood cultures. We conducted a prospective study to determine the accuracy, reporting time (RT), and antimicrobial stewardship impact of DS testing for Staphylococcus aureus positive blood cultures.
Methods. From March-December 2016, first time positive blood cultures for S. aureus were included. Broth from positive blood culture bottles was inoculated to standard media, as well as to Mueller-Hinton agar with a cefoxitin disk. CLSI breakpoints for S. aureus were used to guide interpretation. If DS results were to be reported to clinicians, a penicillin-binding protein 2a (PBP2a) Alere™ test was performed. When the PBP2a result was concordant with the CLSI interpretation, the isolate was reported as either Methicillin-susceptible S. aureus (MSSA) or Methicillin-resistant S. aureus (MRSA). Antibiotic therapy changes made based on reporting of DS results were recorded. In order to determine RT, the following time points were recorded: blood culture positivity, reading of DS, and reporting of SS Results. Of the 100 patients with S. aureus bacteremia, 97 showed pure growth of MSSA or MRSA; 3 patients had mixed infections, all of which were only detected using the DS plates. Average RT was 23 hours and 36h for DS and SS, respectively. There were 32 MRSA isolates, with a cefoxitin zone size range of 6-15 mm (median = 8 mm). PBP2a was performed on 11 isolates; all were positive. Of the 69 MSSA isolates, the cefoxitin range was 22 to 32 mm (median = 27 mm). PBP2a was performed on 26 isolates; all were negative. Direct susceptibility results were reported on 31 patients. Of the 21 patients with MSSA bacteremia, 15 changed therapy from vancomycin/daptomycin to cloxacillin/cefazolin. These results were reported an average of 23 hours prior to SS.
Conclusion. DS testing is an accurate and rapid method to determine whether isolates are MSSA or MRSA. We had no major or minor errors. PBP2a testing was concordant for all isolates tested. DS also has the added benefit of detecting mixed S. aureus infections. Clinicians acted on the reported results of DS testing, with 15/21 (71%) of our patients narrowed to a cloxacillin/cefazolin 23 hours before the availability of SS.
Disclosures. All authors: No reported disclosures. Background. Delays in diagnosis of bloodstream infections (BSI) can lead to adverse outcomes. Matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) can rapidly identify bacteria directly from blood culture bottles. We describe our experience in patients with BSI before and after implementation of MALDI-TOF MS.
MALDI-TOF MS in Adult Inpatients
Methods. Patients: adult inpatients with BSI. Design: pre-intervention group (August-November 2015); bacterial identification and susceptibility testing performed by Vitek®2. Post-intervention group (August-November 2016); bacterial identification on liquid blood culture broth by MALDI-TOF MS; susceptibility testing performed by Vitek®2. Both groups received baseline antimicrobial stewardship program (ASP) intervention. Outcomes: times to bacterial identification, susceptibilities, effective and optimal antibiotics, length of stay (LOS), 30-day readmission and 30-day all-cause mortality. Statistical analysis: univariable analysis performed; continuous variables analyzed using a two-tailed t-test; discrete variables analyzed using a chi-square test or Fisher exact test.
Results. 267 cases of BSI occurring in 256 patients were analyzed (137 pre-intervention, 130 post-intervention). Time to bacterial identification was significantly shorter in the MALDI-TOF MS group (40 vs. 63 hours, P < 0.001). Times to susceptibilities, effective, and optimal antibiotic therapy did not differ between the two groups. There was no significant difference in LOS or 30-day readmission rates. 30-day mortality was significantly higher in the pre-intervention group (25 vs. 13 percent, P = 0.026). The pre-intervention group had significantly more BSI due to multidrug-resistant (MDR) Gram-negative bacteria and vancomycin-resistant enterococci (VRE).
Conclusion. MALDI-TOF MS significantly shortened time to bacterial identification in patients with BSI. Differences in times to effective and optimal antibiotic therapy were not observed. This may be due to high rates of early appropriate empiric antibiotic use at our institution and limited real-time MALDI-TOF MS and ASP interventions. Higher mortality in the pre-intervention group may be due to higher prevalence of multidrug-resistant bacteria.
Disclosures. All authors: No reported disclosures. Background. Rapid initiation of effective antibiotic therapy has been strongly associated with a decrease in mortality in gram-negative (GN) bacteremia. In an effort to improve time to effective antibiotic therapy in the treatment of multi-drug resistant (MDR) GN bacteremia, we implemented Verigene GN Blood Culture (BC-GN) assay, which can rapidly identify GN bacteria at the genus/species level and specific resistance markers from blood cultures within 2 hours of positivity.
Outcomes of Rapid Identification of Multi-Drug
Methods. The objective of this multi-center, pre-post quasi-experimental study was to assess outcomes of Verigene BC-GN in combination with antibiotic stewardship in treatment of MDR GN bacteremia. A retrospective chart review was performed one year prior and four months post-implementation of Verigene BC-GN. Patients > 18 years old with MDR GN bacteremia identified by Verigene BC-GN within 5 days of admission were included. The primary endpoint was time to effective antibiotic therapy for MDR GN bacteremia. Secondary outcomes included overall and ICU length of stay (LOS) and 30-day mortality. Education regarding interpretation of resistance markers and selection of optimal antibiotic therapy was provided to pharmacists and physicians prior to implementation.
Results. A total of 110 patients were included, 86 in the pre-intervention group and 24 in the post-intervention group. Mean time to effective antibiotic therapy decreased significantly from 47.6 ± 23.1 vs. 18.8 ± 9.1 hours, respectively (P < 0.0001). Median overall LOS was 6.0 vs 5.5 days (P = 0.88), ICU LOS was 3.0 vs 4.0 days (P = 0.57), and 30-day mortality was 4.7% vs 4.2% (P = 1) pre and post-implementation, respectively.
